Yuhan Corporation’s $1.25 Billion Licensing Agreement with Janssen

Sidley represented Yuhan Corporation in its licensing agreement with Janssen, a division of Johnson & Johnson, for the development, manufacturing and commercialization of lazertinib, a non-small cell lung cancer drug candidate.

Janssen agreed to pay Yuhan $50 million in upfront money with the potential for significant milestone and royalty payments that could amount to the total of $1.25 billion if the drug earns regulatory approval.

The deal was led by partner Josh Hofheimer (Picture) with counsel Lauren Grau (Dallas).

Involved fees earner: Lauren Grau – Sidley Austin LLP; Joshua Hofheimer – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: Yuhan Corporation;


Author: Ambrogio Visconti